Novel antifungal compounds against Fusarium spp: A systematic review

Fusarium spp. has increased in relevance due to its resistance, high mortality, increasing incidence, and low preventability. The scarce treatment options compelled the development of antifungals with novel mechanisms of action. We conducted a systematic review to report on novel compounds and their activity on Fusarium spp. We searched for terms related to novel antifungals against Fusarium across multiple databases, up to February 2024. From 622 articles, only 15 articles met the eligibility criteria. The antifungals reported were manogepix (10), olorofim (3), ibrexafungerp (1), and MGCD290 (1), evaluated against 480 Fusarium isolates. Manogepix MIC/MECs had broad ranges for most Fusarium species, with notable exceptions like F. solani (MEC: ≤0.12μg/mL) and F. fujikuroi (MEC: ≤0.25μg/mL). Olorofim could be a good candidate for fusariosis treatment based on in vitro activity. Ibrexafungerp and MGCD290 did not show good activity as monotherapy. Further work on applications and development of new treatments against the resistant Fusarium species is essential.